

Special Issue

Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies

Message from the Guest Editors

Thoracic Neuroendocrine Tumors (NETs) are classified into well-differentiated (low-grade typical carcinoids [TCs] and intermediate-grade atypical carcinoids [ACs]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma LCNEC) or small cell lung carcinoma (SCLC) neuroendocrine carcinoma. Despite the increasing incidence of thoracic NETS, awareness [1] and the development of personalized approach therapies in these patients lag. Effective systemic therapies for patients with advanced, progressive neuroendocrine lung tumors are very rare. However, recently, everolimus was associated with significant improvement in progression-free survival in patients with progressive lung neuroendocrine tumors [3]. Further drug development is needed. To date, there is only one biomarker-based clinical trial, S1929, in the poorly differentiated NETs; SCLC that has recently completed enrollment for screening, that attempts to stratify patients with SCLC to receive PARP inhibitor based on SLFN11 that is expressed by more than half of patients with SCLC. Further knowledge of predictive factors and novel therapies is needed.

Guest Editors

Dr. Nagla Abdel Karim

Dr. Asad Ullah

Dr. Jaffar Khan

Prof. Dr. Fernando Mendes

Deadline for manuscript submissions

20 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/142961

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)